Human Fetal Cell Therapy in Huntington's Disease: A Randomized, Multicenter, Phase II Trial.

Published in: Movement disorders : official journal of the Movement Disorder Society (2020)

No clinical benefit was found in this trial. This may have been related to graft rejection. Ectopia and high track number negatively influence the graft outcome. Procedural adjustments substantially improved surgical safety. (ClinicalTrials.gov NCT00190450.) © 2020 International Parkinson and Movement Disorder Society.

Keyphrases

cell therapy
endothelial cells
stem cells
mesenchymal stem cells
clinical trial
phase iii
open label
induced pluripotent stem cells
phase ii
randomized controlled trial
placebo controlled